Advaxis Hires Accomplished Young Scientist

Advaxis Hires Accomplished Young Scientist

NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Jul 12, 2010 - Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, is pleased to announce the hiring of Dr. Reshma Singh as a Senior Scientist.

Dr. Singh received her Ph.D in Immunology at the University of Pennsylvania, completing her doctoral training in the laboratory of Dr. Yvonne Paterson, the scientific founder of Advaxis. It was there that Dr. Singh did some of the formative work on the development of a live attenuated Listeria vaccine for the treatment of cancers associated with the antigen Her2/neu, which is currently in development at Advaxis for the treatment of various cancers, including breast, glioma and others. Subsequently, Dr. Singh completed a post doctoral fellowship in the laboratory of Dr. Peter Cresswell at Yale University, where her work with Listeria and Gamma-interferon-inducible lysosomal thiolreductase (GILT) was published in the journal Nature (2008. 455, 1244-1247) and in the journal Science (2010. 328(5984): 1394 - 1398).

"That Dr. Singh's post-doctoral research has been published in two of the most prestigious medical journals in the world speaks to her skills, abilities and the quality of her work," said Dr. John Rothman, EVP at Advaxis. "She is already a respected member of the live Listeria vaccine community. We are fortunate to have her join us, and look forward building on our exemplary experimental and clinical results to develop safe and effective new treatments for cancer and infectious disease."

About Advaxis, Inc.

Advaxis is a biotechnology company developing proprietary, live, attenuated Listeria monocytogenes (Listeria) vaccines that deliver engineered tumor antigens, which stimulate multiple, simultaneous immunological mechanisms to fight cancer. Today, the Company has nine (9) distinct, cancer-fighting constructs in various stages of development, directly and through strategic collaborations with such recognized sites of excellence as the City of Hope, the Roswell Park Cancer Institute, the National Cancer Institute, the University of Pittsburgh and Cancer Research - UK. Advaxis' technology was developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxis' scientific advisory board.

Please visit the Company's portals: advaxis.com | facebook | twitter | LinkedIn

Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.

 

 

Contact: Advaxis, Incorporated
Conrad F. Mir
Executive Director
732-545-1590 (Office)
732-545-1084 (FAX)
[email protected]
or
Diana Moore
Analyst
732-545-1590 (Office)
732-545-1084 (FAX)
[email protected]

Suggested Articles

The duo will carry out a phase 2 study of BioNTech’s mRNA cancer immunotherapy in combination with Sanofi and Regeneron’s PD-1 blocker, Libtayo.

Merck was purposely cautious during the start of the pandemic when it came to vaccine development but is now slowly but surely ramping up its efforts

The money will equip AlloVir to embark on a broad clinical development program for a phase 3-ready cell therapy that targets five viruses.